Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)’s share price rose 5.6% on Friday . The company traded as high as $152.66 and last traded at $151.78, with a volume of 383,724 shares traded. The stock had previously closed at $143.75.

ICPT has been the subject of a number of research reports. Vetr lowered shares of Intercept Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $164.14 target price for the company. in a research report on Wednesday, April 6th. JMP Securities reiterated a “buy” rating and set a $200.00 target price on shares of Intercept Pharmaceuticals in a research report on Wednesday, March 30th. Cowen and Company reiterated a “buy” rating and set a $212.00 target price on shares of Intercept Pharmaceuticals in a research report on Monday, March 28th. Robert W. Baird reiterated a “buy” rating and set a $32.00 target price on shares of Intercept Pharmaceuticals in a research report on Tuesday, April 5th. Finally, Credit Suisse Group AG reiterated a “buy” rating and set a $200.00 target price on shares of Intercept Pharmaceuticals in a research report on Thursday, April 7th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $203.08.

The firm’s market capitalization is $3.73 billion. The company’s 50 day moving average price is $147.36 and its 200-day moving average price is $133.95.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($5.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.60) by $1.57. During the same period last year, the business earned ($1.78) earnings per share. On average, equities analysts anticipate that Intercept Pharmaceuticals Inc. will post ($16.77) EPS for the current fiscal year.

In related news, CEO Mark Pruzanski sold 714 shares of the company’s stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $145.11, for a total value of $103,608.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Lisa Bright sold 251 shares of the company’s stock in a transaction dated Wednesday, May 25th. The shares were sold at an average price of $137.50, for a total value of $34,512.50. Following the completion of the sale, the insider now directly owns 18,855 shares of the company’s stock, valued at $2,592,562.50. The disclosure for this sale can be found here.

Several hedge funds have recently made changes to their positions in ICPT. Profund Advisors LLC boosted its stake in shares of Intercept Pharmaceuticals by 0.5% in the fourth quarter. Profund Advisors LLC now owns 12,113 shares of the biopharmaceutical company’s stock worth $1,809,000 after buying an additional 65 shares during the period. Rhumbline Advisers boosted its stake in shares of Intercept Pharmaceuticals by 0.7% in the fourth quarter. Rhumbline Advisers now owns 15,849 shares of the biopharmaceutical company’s stock worth $2,367,000 after buying an additional 109 shares during the period. ProShare Advisors LLC boosted its stake in shares of Intercept Pharmaceuticals by 5.9% in the fourth quarter. ProShare Advisors LLC now owns 20,213 shares of the biopharmaceutical company’s stock worth $3,019,000 after buying an additional 1,130 shares during the period. California State Teachers Retirement System boosted its stake in shares of Intercept Pharmaceuticals by 1.4% in the fourth quarter. California State Teachers Retirement System now owns 29,529 shares of the biopharmaceutical company’s stock worth $4,410,000 after buying an additional 400 shares during the period. Finally, Alps Advisors Inc. purchased a new stake in shares of Intercept Pharmaceuticals during the fourth quarter worth about $4,787,000.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.